Literature DB >> 10235225

Severe hepatotoxicity associated with bromfenac sodium.

P L Moses1, B Schroeder, O Alkhatib, N Ferrentino, T Suppan, S D Lidofsky.   

Abstract

Subacute hepatitis and liver failure occurred in a 40-yr-old woman following a 1-month course of treatment with the nonsteroidal anti-inflammatory drug bromfenac. Serologies for hepatitis A, B, and C were negative, as were antinuclear antibodies and ceruloplasmin. A transjugular liver biopsy demonstrated submassive hepatic necrosis. The clinical course was complicated by encephalopathy, fluid retention, and spontaneous bacterial peritonitis, prompting consideration for liver transplantation. With supportive measures, jaundice and fluid retention resolved over a 3-month period. We conclude that prolonged use of bromfenac was the etiological agent in this case, and that this drug can cause severe hepatotoxicity resulting in liver failure.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10235225     DOI: 10.1111/j.1572-0241.1999.01093.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

Review 1.  Drug-induced liver disorders: implications for drug development and regulation.

Authors:  N Kaplowitz
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.

Authors:  Allen D Brinker; Jenna Lyndly; Joseph Tonning; David Moeny; Jonathan G Levine; Mark I Avigan
Journal:  Drug Saf       Date:  2013-12       Impact factor: 5.606

Review 3.  Managing the challenge of chemically reactive metabolites in drug development.

Authors:  B Kevin Park; Alan Boobis; Stephen Clarke; Chris E P Goldring; David Jones; J Gerry Kenna; Craig Lambert; Hugh G Laverty; Dean J Naisbitt; Sidney Nelson; Deborah A Nicoll-Griffith; R Scott Obach; Philip Routledge; Dennis A Smith; Donald J Tweedie; Nico Vermeulen; Dominic P Williams; Ian D Wilson; Thomas A Baillie
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

4.  Corneal sensitivity after topical bromfenac sodium eye-drop instillation.

Authors:  Kaori Yanai; Jane Huang; Kazuaki Kadonosono; Eiichi Uchio
Journal:  Clin Ophthalmol       Date:  2013-04-17

Review 5.  Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges.

Authors:  John R Senior
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

Review 6.  Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature.

Authors:  Joseph William Clinton; Sara Kiparizoska; Soorya Aggarwal; Stephanie Woo; William Davis; James H Lewis
Journal:  Drug Saf       Date:  2021-09-17       Impact factor: 5.606

7.  Proteome Exploration of Legionella pneumophila To Identify Novel Therapeutics: a Hierarchical Subtractive Genomics and Reverse Vaccinology Approach.

Authors:  Md Tahsin Khan; Araf Mahmud; Mahmudul Hasan; Kazi Faizul Azim; Musammat Kulsuma Begum; Mohimenul Haque Rolin; Arzuba Akter; Shakhinur Islam Mondal
Journal:  Microbiol Spectr       Date:  2022-07-12

8.  Identification and characterization of potential therapeutic candidates in emerging human pathogen Mycobacterium abscessus: a novel hierarchical in silico approach.

Authors:  Buvaneswari Shanmugham; Archana Pan
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.